低病毒载量HBV感染者肝脏炎症及纤维化情况分析

姜曼蕾; 许飞; 张伦理

doi:10.3969/j.issn.1001-5256.2023.06.008

低病毒载量HBV感染者肝脏炎症及纤维化情况分析

DOI: 10.3969/j.issn.1001-5256.2023.06.008

姜曼蕾^1, , ,,
许飞¹,
张伦理²

1.
赣州市第五人民医院疑难肝病科, 江西赣州 341000
2.
南昌大学第一附属医院感染科, 南昌 330006

基金项目:

江西省卫生健康委科技基金项目 (202212322);

赣州市科技局基金项目 (GZ2020ZSF294)

伦理学声明：本研究方案于2022年7月1日经由赣州市第五人民医院伦理委员会审批，批号：2022008。

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：姜曼蕾负责内容资料收集、分析，文章撰写；许飞负责文章指导；张伦理负责文章指导、审校。

详细信息

通信作者:
姜曼蕾，lffjml@163.com (ORCID：0000-0003-0971-6219)

计量
- 文章访问数: 497
- HTML全文浏览量: 42
- PDF下载量: 75
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-27
- 录用日期: 2022-12-12
- 出版日期: 2023-06-20

Liver inflammation and fibrosis in HBV-infected patients with a low viral load

Manlei JIANG^{1
, ,
,},
Fei XU¹,
Lunli ZHANG²

1.
Department of Difficult Hepatology, Ganzhou Fifth People's Hospital, Ganzhou, Jiangxi 341000, China
2.
Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Research funding:

Science and Technology Fund Project of Jiangxi Provincial Health Commission (202212322);

Ganzhou Science and Technology Bureau Fund Project (GZ2020ZSF294)

More Information

Corresponding author: JIANG Manlei, lffjml@163.com (ORCID: 0000-0003-0971-6219)

摘要

摘要: 目的探讨低病毒载量慢性HBV感染者肝脏炎症、纤维化情况。方法选取2019年4月—2022年6月赣州市第五人民医院就诊HBsAg阳性患者，筛选出20 IU/mL＜HBV DNA＜2 000 IU/mL患者41例，完善血生化、肝硬度、肝穿刺病理检查，明确肝脏炎症和纤维化情况；根据HBV DNA、ALT、肝硬度值、年龄对比分析肝脏炎症情况。计数资料组间比较采用χ²检验。结果 36.59%(15/41)低病毒载量HBV感染者肝脏炎症和/或纤维化≥G2/S2。15例慢性乙型肝炎患者中，HBV DNA为＞200~2 000 IU/mL患者11例(73.33%)，HBV DNA为20~200 IU/mL患者4例(26.67%)；肝脏炎症活动度分级G2占比73.33%(11/15)、纤维化程度分期S2占比46.67%(7/15)；ALT≤30 U/L占比46.67%(7/15)；年龄≥30岁占比86.66%(13/15)；LSM＞17 kPa占比6.67%(1/15)，LSM 12.4~17 kPa占比46.67%(7/15)，LSM 9.4~12.4 kPa占比33.33%(7/15)。结论低病毒载量慢性HBV感染者有较高的炎症和纤维化进展风险；ALT水平不能作为低病毒载量HBV感染者是否抗病毒治疗的依据；瞬时弹性成像肝硬度检测可作为筛查低病毒载量慢性乙型肝炎患者的无创检查，当低病毒载量HBV感染者＞30岁、肝硬度值持续＞9.4 kPa时应考虑给予抗病毒治疗。
- 乙型肝炎, 慢性 /
- 病毒载量 /
- 肝纤维化
Abstract: Objective To investigate liver inflammation and fibrosis in patients with chronic HBV infection with a low viral load. Methods Among the HBsAg-positive patients who attended Ganzhou Fifth People's Hospital from April 2019 to June 2022, 41 patients with 20 IU/mL < HBV DNA < 2 000 IU/mL were selected and underwent the examinations of blood biochemistry, liver stiffness measurement (LSM), and liver biopsy to clarify liver inflammation and fibrosis. Liver inflammation was analyzed according to HBV DNA, alanine aminotransferase (ALT), LSM, and age. The chi-square test was used for comparison of categorical data between groups. Results Among the 41 patients, 15 (36.59%) had liver inflammation grade ≥G2 and/or liver fibrosis stage ≥S2. Among these 15 patients, 11 (73.33%) had an HBV DNA level of > 200-2 000 IU/mL and 4 (26.67%) had an HBV DNA level of 20-200 IU/mL; the patients with G2 liver inflammation accounted for 73.33% (11/15), and those with S2 liver fibrosis accounted for 46.67% (7/15); the patients with ALT ≤30 U/L accounted for 46.67% (7/15); the patients aged ≥30 years accounted for 86.66% (13/15); the patients with LSM > 17 kPa accounted for 6.67% (1/15), those with an LSM value of 12.4-17 kPa accounted for 46.67% (7/15), and those with an LSM value of 9.4-12.4 kPa accounted for 33.33% (5/15). Conclusion Patients with chronic HBV infection and low-level viremia have a relatively high risk of progression of inflammation and fibrosis. ALT level cannot be used as a basis for antiviral therapy in HBV-infected people with a low viral load. LSM based on transient elastography can be used as a noninvasive test to screen for CHB patients with a low viral load, and antiviral therapy should be considered when HBV-infected patients with a low viral load have an age of > 30 years and an LSM value of > 9.4 kPa persistently.
- Hepatitis B, Chronic /
- Viral Load /
- Hepatic Fibrosis

HTML全文

参考文献(16)

[1]	SETO WK, LO YR, PAWLOTSKY JM, et al. Chronic hepatitis B virus infection[J]. Lancet, 2018, 392(10161): 2313-2324. DOI: 10.1016/S0140-6736(18)31865-8.
[2]	HUTIN Y, NASRULLAH M, EASTERBROOK P, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(28): 773-777. DOI: 10.15585/mmwr.mm6728a2.
[3]	ZHANG R, TANG YY, YU Q, et al. Analysis on ten-year data of individualized programs to prevent mother-to-child transmission of hepatitis B virus[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2021, 15(5): 303-310. DOI: 10.3877/cma.j.issn.1674-1358.2021.05.003. 张荣, 唐雍艳, 喻茜, 等. 个体化方案阻断乙型肝炎病毒母婴传播十年数据分析[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(5): 303-310. DOI: 10.3877/cma.j.issn.1674-1358.2021.05.003.
[4]	CAO XZ, YI W, LIU XM, et al. The immune response and influencing factor of hepatitis B virus vaccine on 3-year-old children born to mothers infected with HBV[J/OL]. Chin J Liver Dis (Electronic Version), 2022, 14(2): 57-62. DOI: 10.3969/j.issn.1674-7380.2022.02.009. 曹秀贞, 易为, 刘雪梅, 等. HBV感染母亲所生儿童3岁时乙肝疫苗免疫应答情况及影响因素[J/OL]. 中国肝脏病杂志(电子版), 2022, 14(2): 57-62. DOI: 10.3969/j.issn.1674-7380.2022.02.009.
[5]	LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[6]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[7]	China Hepatitis Prevention and Control Foundation, Infectious Diseases Branch of Chinese Medical Association, Hepatology Branch of Chinese Medical Association and Hepatology Professional Committee of Chinese Research Hospital Association. Expert consensus on transient elastography for the diagnosis of liver fibrosis (2018 updated edition)[J]. Chin J Hepatol, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004. 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27(3): 182-191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
[8]	LOK AS, MCMAHON BJ. Chronic hepatitis B[J]. Hepatology, 2007, 45(2): 507-539. DOI: 10.1002/hep.21513.
[9]	LIAW YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int, 2009, 29(Suppl 1): 100-107. DOI: 10.1111/j.1478-3231.2008.01941.x.
[10]	FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.
[11]	HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.
[12]	MA JW, ZHAI YZ. Progress on treatment of immune tolerance phase of hepatitis B virus infection[J/OL]. Chin J Liver Dis(Electronic Version), 2022, 14(2): 32-36. DOI: 10.3969/j.issn.1674-7380.2022.02.005. 马俊雯, 翟永贞. 乙型肝炎病毒感染免疫耐受期治疗进展[J/OL]. 中国肝脏病杂志(电子版), 2022, 14(2): 32-36. DOI: 10.3969/j.issn.1674-7380.2022.02.005.
[13]	Hepatology Branch of Chinese Medical Association. Expert opinion on expanding antiviral therapy for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060. 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
[14]	WANG C, WANG C, DEUBNER H, et al. High prevalence of significant fibrosis in patients with immunotolerance to chronic hepatitis B infection[J]. Hepatology, 2005, 42(Suppl 1): A573.
[15]	ZHUANG H. Should chronic hepatitis B be treated in the uncertain phase?[J]. J Clin Hepatol, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007. 庄辉. 不确定期慢性乙型肝炎应否治疗?[J]. 临床肝胆病杂志, 2021, 37(9): 2033-2036. DOI: 10.3969/j.issn.1001-5256.2021.09.007.
[16]	SUN Y, CHANG J, LIU X, et al. Mortality trends of liver diseases in mainland China over three decades: an age-period-cohort analysis[J]. BMJ Open, 2019, 9(11): e029793. DOI: 10.1136/bmjopen-2019-029793.